Low-expressing Breast Cancer
📧 Sign up to get email alerts when something new happens for Low-expressing Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
This clinical trial update reports real-world outcomes of trastuzumab deruxtecan (Enhertu) in Canadian patients with unresectable or metasta…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer [NA]
A clinical trial update indicates a study evaluating trastuzumab deruxtecan using PERCIST criteria for HER2-low metastatic breast cancer, wh…
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating alternating regimens of Sacituzumab govitecan and Trastuzumab deruxtecan in patients with metastatic …
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis [Phase 2]
Phase 2 clinical trial update on trastuzumab deruxtecan (T-DXd) with or without bevacizumab for HER2-low breast cancer with brain metastases…
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial [Phase 2]
Phase II neoadjuvant trial assessing pyrotinib in combination with chemotherapy for HER2-low-expressing, hormone receptor-positive breast ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.